Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 11/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735209 | 0.89 | PDE9A (0.80) | PDE9AMAPKAPK2PIK3CAPIK3CDPIK3CG | |
| SCHEMBL2735207 | 0.88 | PDE9A (0.79) | PDE9AMAPKAPK2PIK3CAPIK3CDPIK3CG | |
| SCHEMBL2735235 | 0.85 | PDE9A (0.73) | PDE9AALDH1A1NPSR1PDE5A | |
| SCHEMBL2735208 | 0.83 | PDE9A (0.71) | PDE9AMAPKAPK2PIK3CAPIK3CDPIK3CG | |
| SCHEMBL213042 | 0.82 | PDE9A (0.69) | PDE9APIK3CAALDH1A1NPSR1 | |
| SCHEMBL212444 | 0.82 | PDE9A (0.69) | PDE9APIK3CAALDH1A1NPSR1PDE5A | |
| SCHEMBL2735211 | 0.80 | PDE9A (0.67) | PDE9AALDH1A1NPSR1PDE5A | |
| SCHEMBL215586 | 0.80 | PDE9A (0.67) | PDE9AALDH1A1NPSR1 | |
| SCHEMBL2735227 | 0.79 | PDE9A (0.65) | PDE9AALDH1A1NPSR1 | |
| SCHEMBL2735245 | 0.79 | PDE9A (0.65) | PDE9AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709009-B1 | 6-AMINO-5-CYANO-PYRIMIDINE-4-ONES USED FOR IMPROVING PERCEPTION, POWER OF CONCENTRATION, LEARNING EFFICIENCY, AND/OR MEMORY POWER | BOEHRINGER INGELHEIM INT (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| CN-102382063-A | 6-amino-5-cyano-pyrimidine-4-ones compound used for improving perception, power of concentration, learning efficiency, and/or memory power | BOEHRINGER INGELHEIM INT | 2012-03-21 | — | — | CN | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| CN-1926117-B | 6-amino-5-cyano-pyrimidin-4-ones for improved perception, attention, learning efficiency, and/or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-07 | — | — | CN | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1890702-A1 | USE OF CYANOPYRIMIDINES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-02-27 | — | — | EP | disclosed |
| CN-1926117-A | 6-amino-5-cyano-pyrimidin-4-ones for improved perception, attention, learning efficiency, and/or memory | BAYER HEALTHCARE AG (DE) | 2007-03-07 | — | — | CN | disclosed |
| WO-2006125554-A1 | USE OF CYANOPYRIMIDINES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125554-A1 | USE OF CYANOPYRIMIDINES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2005068436-A1 | 6-AMINO-5-CYANO-PYRIMIDINE-4-ONES USED FOR IMPROVING PERCEPTION, POWER OF CONCENTRATION, LEARNING EFFICIENCY, AND/OR MEMORY POWER | BAYER HEALTHCARE AG (DE) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255118-A1 | Cyanopyrimidinones | CACYBP, CHRM4, CHRNA4 | PDE9A 280/4885MAPKAPK2 520/4885PIK3CA 1630/4885 |
| US-20110207735-A1 | CYANOPYRIMIDINONES | CACYBP, CHRM4, CHRNA4 | PDE9A 280/4885MAPKAPK2 520/4885PIK3CA 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.